Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 3/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450505 | 0.84 | MEN1 (0.65) | MEN1KMT2AUSP2GAAKEAP1 | |
| SCHEMBL125785 | 0.84 | MEN1 (0.65) | MEN1KMT2AUSP2GAAKEAP1 | |
| SCHEMBL10735111 | 0.83 | MEN1 (0.81) | MEN1KMT2AUSP2GAAKEAP1 | |
| SCHEMBL10357074 | 0.82 | MEN1 (0.68) | MEN1KMT2AUSP2GAAKEAP1 | |
| SCHEMBL18241805 | 0.82 | SNCA (0.47) | ALDH1A1ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL27927099 | 0.82 | MEN1 (0.54) | MEN1KMT2AUSP2GAAKEAP1 | |
| SCHEMBL93420 | 0.81 | MEN1 (0.78) | MEN1KMT2AUSP2GAAKEAP1 | |
| SCHEMBL29375096 | 0.81 | MEN1 (0.78) | MEN1KMT2AUSP2GAAKEAP1 | |
| SCHEMBL29748711 | 0.81 | HSD17B1 (0.59) | ESR1ESR2HSD17B1HSD17B2CES2 | |
| SCHEMBL27661242 | 0.81 | HSD17B1 (0.59) | ESR1ESR2HSD17B1HSD17B2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370349-B2 | Functionalised benzopyran compounds and use thereof | Kazia Therapeutics Limited (AU) | 2019-08-06 | — | — | US | disclosed |
| US-20180141925-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | Kazia Therapeutics Limited (AU) | 2018-05-24 | — | — | US | disclosed |
| EP-2953938-B1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | Novogen ltd (AU) | 2017-08-02 | — | — | EP | disclosed |
| US-9701655-B2 | Functionalised benzopyran compounds and use thereof | NOVOGEN LIMITED (AU) | 2017-07-11 | — | — | US | disclosed |
| US-20160340329-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | VIVESTO AB (SE) | 2016-11-24 | — | — | US | disclosed |
| EP-2953938-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | Novogen Ltd. (AU) | 2015-12-16 | — | — | EP | disclosed |
| WO-2015117202-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | NOVOGEN LIMITED (AU) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141925-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | BRCA1, BRAP, EP300 | MEN1 7/4885KMT2A 1486/4885USP2 2117/4885 |
| US-20160340329-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOF | BRCA1, VHL, NQO1 | MEN1 2754/4885KMT2A 539/4885USP2 3699/4885 |
| US-10370349-B2 | Functionalised benzopyran compounds and use thereof | BRCA1, BRAP, EP300 | MEN1 7/4885KMT2A 1486/4885USP2 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.